DIRS.INFO The most relevant business & tech news

☆ Atlas of cells offers a milestone leap in understanding of the human body
▼ + stars: | 2024-11-21 | by ( Katie Hunt | ) edition.cnn.com time to read: +7 min

New research based on the findings, published in several papers Wednesday in Nature and its sister journals, represents a “leap in understanding of the human body,” according to the Human Cell Atlas consortium. Regev compared scientific knowledge of cell biology before the Human Cell Atlas initiative with a “15th century map.”“Now, years later, the resolution of the map is a lot higher,” she said. The cell atlas aims to fill in a missing link between genes, diseases and treatment therapies. During the Covid-19 pandemic, the Human Cell Atlas community used the available data to reveal that the nose, eyes and mouth were most vulnerable to infection. “It was only clear through the Human Cell Atlas data that those cells were … entry points before the virus continued into the internal organs.

Persons: —, ”, Aviv, Daniel Montoro “, we’ve, Regev, “, Sarah Teichmann, Ken, Blain, Robert Hooke, ” Teichmann, Jeremy Farrar, ” Farrar Organizations: CNN, Human Cell Atlas, Genome, Cell, Google, Human, Human Cell, Cambridge Stem Cell, UK’s University of Cambridge, Wellcome Sanger Institute, Institut, la Vision, HCL, Lyon, World Health Organization Locations: Nature, Genentech, South San Francisco , California, Cambridge, England, Paris, Lyon English

☆ Nvidia's AI ambitions in medicine and health care are becoming clear
▼ + stars: | 2024-03-24 | by ( Michelle Castillo | ) www.cnbc.com time to read: +3 min

Last week, Nvidia announced deals with Johnson & Johnson for use of generative AI in surgery, and with GE Healthcare to improve medical imaging. "Health care, whether it's biotechnology, chemicals, or drug discovery is a very powerful area." About 41 percent of biotech CEOs surveyed by EY in late 2023 said they were looking at "concrete" ways generative AI could be used for their companies. "This is very high for my experience, having been 30 years in this industry," Ural said. It also partnered in 2021 with Schrödinger for drug discovery.

Persons: Johnson, Raj Joshi, It's, EY, it's, Colette Kress, Roche's Genentech Organizations: Nvidia, Johnson, GE Healthcare, Companies, NVIDIA, NVIDIA BioNeMo Locations: Arda, Americas, Ural, NVIDIA Clara

☆ New data shows asthma medicine may help reduce severe reactions in people with multiple food allergies
▼ + stars: | 2024-02-25 | by ( Amanda Musa | ) edition.cnn.com time to read: +9 min

CNN —A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. There is no cure for food allergies, and the only other FDA-approved treatment is Palforzia, an oral immunotherapy for peanut allergies in children between 4 and 17 years old. “But the reality is that most of our patients don’t just have peanut allergy,” Wood added. For people who have multiple severe food allergies and even moderate to severe allergic asthma, Casale says, Xolair might be the best treatment option. Xolair does not eliminate food allergies, and unlike with some environmental allergies such as pollen, many people never outgrow them, Casale added.

Persons: ”, Sharon Chinthrajah, “, ” Xolair, Robert Wood, ” Wood, Xolair, Wood, omalizumab, Thomas Casale, Palforzia, Casale, they’ve, ” Lindsey Mathias, Dr, Sanjay Gupta, Chinthrajah, “ We’re Organizations: CNN, New England, of Medicine, US Food and Drug Administration, Stanford University, of Allergy, Immunology, Johns Hopkins Children’s, Genentech, Novartis, FDA, National Institutes of Health, University of South, American Academy of Allergy Asthma, CNN Health, Xolair Locations: anaphylaxis, Eudowood, Johns, University of South Florida Tampa

A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug omalizumab, became the first medication approved to reduce allergic reactions caused by accidental exposure to food triggers. An estimated 17 million people in the U.S. have the type of food allergies that can cause rapid, serious symptoms, including severe, whole-body reactions that are potentially deadly. Wood estimated that 25% to 50% of people with food allergies, particularly children and young adults, would elect to use Xolair. The drug has been used “off-label” to treat food allergies, said Dr. Ruchi Gupta, director of the Center for Food Allergy & Asthma Research at Northwestern University.

Persons: Xolair, ”, Robert Wood, Wood, Ruchi Gupta Organizations: U.S . Food, Drug Administration, Johns Hopkins Children’s Center, FDA, National Institutes of Health, Center for Food Allergy, Asthma Research, Northwestern University, drugmakers Novartis, Roche, Genentech, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S

☆ Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources
▼ + stars: | 2023-11-07 | by ( Svea Herbst-Bayliss | ) www.reuters.com time to read: +3 min

NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical (BMRN.O) and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter. Elliott declined to comment, while a representative for BioMarin did not immediately respond to a request for comment. BioMarin shares rose 12% to $85.36 on the news in morning trading in New York on Tuesday. Prior to news of Elliott's engagement, BioMarin shares were down 24% year-to-date, significantly underperforming the iShares Biotechnology ETF (IBB.O), which is down 8.6%. Elliott also successfully pushed for drug makers Alexion Pharma (AZN.L) and Allergan (ABBV.N) to be sold.

Persons: Elliott, BioMarin, hemophilia, Jean, Jacques Bienaime, Alexander Hardy, Jefferies, Bienaime, Harvey, Richard Meier, Svea Herbst, Bayliss, Jamie Freed Organizations: Investment Management, BioMarin Pharmaceutical, Biotechnology, Alexion Pharma, Svea, Thomson Locations: BioMarin, San Rafael , California, West Palm Beach , Florida, New York

☆ England to rollout world-first seven-minute cancer treatment jab
▼ + stars: | 2023-08-29 | by ( ) www.reuters.com time to read: +2 min

Boxes of Tecentriq from Genentech are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S., July 22, 2022. REUTERS/George Frey/File Photo Acquire Licensing RightsAug 29 (Reuters) - Britain's state-run national health service will be the first in the world to offer an injection that treats cancer to hundreds of patients in England which could cut treatment times by up to three quarters. The treatment is currently offered by transfusion to NHS patients with a range of cancers, including lung, breast, liver and bladder. NHS England said it expected the majority of around 3,600 patients starting the treatment of atezolizumab every year in England to switch onto the time-saving injection. But added that patients receiving intravenous chemotherapy in combination with atezolizumab may remain on the transfusion.

Persons: George Frey, Dr Alexander Martin, atezolizumab, Marius Scholtz, Genentech, Roche, Farouq Suleiman, Sandra Maler Organizations: Huntsman Cancer Institute, University of Utah, REUTERS, Medicines, Healthcare, Agency, Foundation Trust, Roche Products, Thomson Locations: Genentech, Salt Lake City , Utah, U.S, England, West Suffolk

☆ Europe markets open lower as investors digest earnings and U.S. rating downgrade
▼ + stars: | 2023-08-02 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: 1 min

A subsidiary of Swiss drugmaker Roche, Genentech, accused a Novartis unit, Sandoz, of infringing one of its patents, according to a complaint filed in a New Jersey court Monday. The patent covers the drug Esbriet, which is used as a treatment for certain types of lung disease. Genentech said in the complaint that Sandoz's breach of the patent was "knowing, reckless, and willful" and had resulted in "significant damage " to its company. Roche has previously attempted to sue Sandoz over the same drug, but the lawsuit was thrown out in March 2022 after a U.S. judge found that parts of the Genentech patents were invalid. Shares in both Roche and Novartis were down 1.4% in the first hour of trading.

Persons: Swiss drugmaker Roche, Genentech, Roche, Sandoz, — Hannah Ward, Glenton Organizations: Swiss, Novartis Locations: New Jersey, U.S, Roche

☆ University Departures Put Student Journalists in Spotlight
▼ + stars: | 2023-07-19 | by ( Katie Robertson | More About Katie Robertson | ) www.nytimes.com time to read: +1 min

Mr. Baker, 18, resurfaced claims in a Nov. 29 article for The Stanford Daily that neuroscience research papers in which Dr. Tessier-Lavigne was listed either as principal author or co-author had altered imagery. The claims had been repeated over the years on PubPeer, a website that allows scientists to discuss research. The next day, Stanford University opened an investigation into Dr. Tessier-Lavigne with a panel of outside scientists. Dr. Tessier-Lavigne denied those claims. “That allegation appears to be mistaken, as Genentech has stated,” the panel’s report said, though it noted “multiple problems” with the 2009 study.

Persons: ”, Theo Baker, . Baker, Tessier, Lavigne, Lavigne “, Genentech, . Tessier Organizations: Stanford Daily, Stanford, Stanford University

☆ Stanford President Will Resign After Report Found Flaws in His Research
▼ + stars: | 2023-07-19 | by ( Stephanie Saul | More About Stephanie Saul | ) www.nytimes.com time to read: +1 min

Following months of intense scrutiny of his scientific work, Marc Tessier-Lavigne announced Wednesday that he would resign as president of Stanford University after an independent review of his research found significant flaws in studies he supervised going back decades. The review, conducted by an outside panel of scientists, refuted the most serious claim involving Dr. Tessier-Lavigne’s work — that an important 2009 Alzheimer’s study was the subject of an investigation that found falsified data and that Dr. Tessier-Lavigne had covered it up. The panel concluded that the claims “appear to be mistaken” and that there was no evidence of falsified data or that Dr. Tessier-Lavigne had otherwise engaged in fraud. But the review also stated that the 2009 study, conducted while he was an executive at the biotech company Genentech, had “multiple problems” and “fell below customary standards of scientific rigor and process,” especially for such an influential paper.

Persons: Marc Tessier, Lavigne, Tessier, “ Organizations: Stanford University

☆ Stanford University president to quit after review finds flaws in his research
▼ + stars: | 2023-07-19 | by ( Brad Brooks | ) www.reuters.com time to read: +2 min

July 19 (Reuters) - The president of Stanford University, one of the most prestigious U.S. schools, announced plans on Wednesday to resign his post after an independent review ordered by its board of trustees found flaws in his research as a neuroscientist. Those allegations were in connection with Alzheimer's disease research carried out when Tessier-Lavigne was the executive vice president of research drug discovery at the U.S. biotechnology company Genentech Inc. But the review of 12 research papers dating over two decades found that when concerns about the research were raised, "Tessier-Lavigne failed to decisively and forthrightly correct mistakes in the scientific record." As a result of the review, Tessier-Lavigne said he was going to retract three papers and correct another two. The board of trustees named Richard Saller, a professor in Stanford's Department of Classics, as interim president beginning Sept. 1.

Persons: Marc Tessier, Lavigne, Tessier, " Tessier, Richard Saller, Brad Brooks, Will Dunham, Donna Bryson Organizations: Stanford University, Stanford, University, Genentech Inc, Stanford's Department of Classics, Thomson Locations: U.S, Palo Alto , California, Lubbock , Texas

☆ These 3 stocks are troubled but I'm not ready to give up
▼ + stars: | 2023-06-20 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Johnson & Johnson (JNJ) is also a head-scratcher. EL YTD mountain Estee Lauder YTD performance Estee Lauder just shocks me. Estee Lauder, at the end of this week, acted like there was something going on, but I can't fathom what it might be. That said, there's a suit going on in Northern California with a dying 24-year-old man claiming that excess use of J & J baby powder is to blame, which could make $8.9 billion look small. Bottom line Johnson & Johnson, Estee Lauder and Danaher are why this business of stock picking and running a portfolio can be so daunting.

Persons: Estee Lauder, Johnson, Danaher's, Lauder, Houdini, Fabrizio Freda, Alex Gorsky, there's, Danaher, Jim Cramer's, Jim Cramer, Jim, Spencer Platt Organizations: CNBC, New York Stock Exchange, Getty Locations: Swiss, Roche, China, Cava, CAVA, Northern California, New York City

☆ BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit
▼ + stars: | 2023-05-10 | by ( ) www.reuters.com time to read: +2 min

FRANKFURT, May 10 (Reuters) - Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech (22UAy.DE) potentially bodes well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients. Pancreatic cancer is among the most deadly forms of cancer because it typically grows undetected until an effective treatment is too late. The trial focused on pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of pancreatic cancer cases. Nature covers a wide range of topics in science and technology beyond medicine. Among the eight trial participants with a detectable immune response, there was no evidence of cancer recurrence 18 months after surgery, while the median time to recurrence was 13.4 months among the non-responders.

☆ Bristol Myers CEO Caforio steps down
▼ + stars: | 2023-04-26 | by ( ) www.reuters.com time to read: +1 min

[1/2] A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File PhotoCompanies Bristol-Myers Squibb Co FollowApril 26 (Reuters) - Bristol Myers Squibb Co (BMY.N) said on Wednesday CEO Giovanni Caforio, who has been in the role since 2015, has decided to step down from his position. Outgoing CEO Giovanni will continue as executive chairman of the company's board. Bristol Myers is due to report first-quarter financial results on Thursday. Bristol Myers shares rose 0.39% to $68.29 in after-hours trading.

☆ Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
▼ + stars: | 2023-04-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows. The findings also come as Eisai and Biogen try to regain their footing after the polarizing approval and disastrous rollout of its other Alzheimer's disease therapy, aduhelm, last year. In the analysis, Alzheimer's patients stopped taking Leqembi after 18 months in a phase two clinical trial and later resumed the treatment in an extension trial. Amyloid is a protein that builds up on the brain in Alzheimer's patients and disrupts cell function. That means Alzheimer's disease progressed at a slower rate in patients who received Leqembi compared to those who took the placebo during the clinical trial.

☆ Creating more Equitable Health Care
▼ + stars: | 2023-04-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCreating more Equitable Health CareAs part of their Equality of Opportunity Initiative, the U.S. Chamber of Commerce is working to develop real, sustainable solutions to help close race-based opportunity gaps in a number of key areas including health care. Forging the path forward on this issue requires building strong partnerships among government, education and private business including with partners like Genentech. 20:26 an hour ago

March 1 (Reuters) - Roche's Genentech Inc (ROGING.UL) sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri. Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later. According to Genentech, Biogen has refused to pay royalties on any Tysabri sales since the patents expired more than four years ago. It said Biogen owes royalties for "most or all" of the Tysabri sold in "2019 and beyond," which it said was made with the patented technology before the patents expired. The case is Genentech Inc v. Biogen MA Inc, U.S. District Court for the Northern District of California, No.

☆ 'P-Valley' star Brandee Evans shares how she balances her career with being a caregiver to her mother who has MS
▼ + stars: | 2023-02-16 | by ( Renée Onque | ) www.cnbc.com time to read: +1 min

Brandee Evans does just as much work off-screen as she does in her role as "Mercedes" on the popular TV series, "P-Valley." When she's not filming, you can find Evans caring for her mother, who has multiple sclerosis. I literally was breaking down in my health, my mental health and my physical health, because I was trying to do it all," says Evans. Still, Evans equates managing her work and caregiving with walking "on a tightrope." Here's what Evans has learned along the way and tips for those who help care for a sick loved one.

☆ Factbox: Bayer's new CEO: long-time Roche, Genentech executive, Bill Anderson
▼ + stars: | 2023-02-08 | by ( ) www.reuters.com time to read: +1 min

LONDON, Feb 8 (Reuters) - Bayer (BAYGn.DE) bowed to investor pressure on Wednesday and named Bill Anderson, most recently head of Roche's (ROG.S) pharmaceuticals business, to take over from Werner Baumann as its CEO in June. Here are some key facts about the career about the 56-year-old American who will run the nearly 160-year-old German drugmaker:He is a chemical engineer by education and has worked for Genentech and its parent Roche since 2006CAREER:1989: started his career at Ethyl Corp, a U.S.-based fuel additives company, with postings in Belgium and the Netherlands1995: joined Raychem Corp., a U.S. technology and electronics firm1997-2006: worked at Biogen (BIIB.O) in the United States, UK and Ireland; roles included running its neurology unit, its largest business2006: joined Genentech as senior vice president, immunology and ophthalmology2010: became svp BioOncology2013: left Genentech to become global product strategy head/chief marketing officer at Genentech's parent company, Roche (ROG.S)2016: returned to Genentech as head of North American operations2017: appointed chief executive officer at Genentech2019-2023: CEO of Roche PharmaceuticalSources: Roche and BayerCompiled by Josephine Mason. Editing by Jane MerrimanOur Standards: The Thomson Reuters Trust Principles.

☆ Brazilian soccer legend Pelé died of colon cancer. Here are the cutting-edge clinical trials trying to find new treatments for the disease.
▼ + stars: | 2022-12-30 | by ( Sarah Braner | ) www.businessinsider.com time to read: +4 min

The Brazilian soccer legend Pelé died of colon cancer Thursday at 82. Colon cancer is the third most common cancer, affecting almost 2 million people each year. Colorectal cancer is the third most common cancer, according to the World Cancer Research Fund International. Pelé isn't the only celebrity to have died of colon cancer in recent years — the Black Panther star Chadwick Boseman died of the disease in 2020 at the age of 43. Here are the cutting-edge phase-three clinical trials for colon cancer, in order of how recently they began.

☆ Roche's head of pharmaceuticals to leave company
▼ + stars: | 2022-12-12 | by ( ) www.reuters.com time to read: +1 min

ZURICH, Dec 12 (Reuters) - Roche's (ROG.S) head of its pharmaceuticals division will leave the drugmaker at the end of the year, the Swiss company said on Monday, as it confirmed other parts of its succession plan. Former Genentech boss Bill Anderson "has decided to pursue opportunities outside of Roche," Roche said, with a successor due to be named by March 2023. Schinecker will replace Severin Schwan, who is slated to become chairman after 14 years as CEO of Roche. He has been instrumental in shaping Roche’s transformation and I wish him all the best for the future," Schwan said in a statement. He had been CEO of Roche's pharmaceuticals business since 2019.

☆ $6.1 billion cloud startup Benchling hired executives from top software companies like Atlassian, Workday, and ServiceNow as it looks to its next phase of growth
▼ + stars: | 2022-08-25 | by ( Paayal Zaveri | ) www.businessinsider.com time to read: +5 min

Benchling, which makes cloud R&D software for life sciences companies, boomed during the pandemic. Benchling has grown in size and valuationBenchling makes cloud software to help life sciences companies make their research and development more efficient. He sees a huge opportunity to bring life sciences companies into the cloud, especially given that there aren't many other software companies serving that specific market. The company's new CTO and product chief will be key to making that happen. Shawna Wolverton, chief product officer at Benchling BenchlingWolverton, meanwhile has experience in helping build out Salesforce's platform, which in turn fostered an ecosystem around the cloud giant's products.

Search resuls for: "Genentech"

21 mentions found